argenx NV ADR Asset Resilience Ratio
argenx NV ADR asset resilience ratio. argenx NV ADR (ARGX) has an Asset Resilience Ratio of 15.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does argenx NV ADR carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of argenx NV ADR (2012–2025)
Asset resilience ratio of argenx NV ADR from 2012 to 2025. This chart shows how argenx NV ADR's Asset Resilience Ratio has changed over time. See how much free cash does argenx NV ADR generate to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down argenx NV ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ARGX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.60 Billion | 15.95% |
| Total Liquid Assets | $1.60 Billion | 15.95% |
Asset Resilience Insights
- Good Liquidity Position: argenx NV ADR maintains a healthy 15.95% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
argenx NV ADR Industry Peers by Asset Resilience Ratio
Compare argenx NV ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
argenx NV ADR Asset Resilience Ratio by Year (2012–2025)
argenx NV ADR asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for argenx NV ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.93% | $948.75 Million | $8.68 Billion | -19.37pp |
| 2024-12-31 | 30.29% | $1.88 Billion | $6.20 Billion | +5.39pp |
| 2023-12-31 | 24.90% | $1.13 Billion | $4.54 Billion | -19.51pp |
| 2022-12-31 | 44.41% | $1.39 Billion | $3.13 Billion | +9.25pp |
| 2021-12-31 | 35.16% | $1.00 Billion | $2.85 Billion | +0.95pp |
| 2020-12-31 | 34.20% | $779.65 Million | $2.28 Billion | -35.88pp |
| 2019-12-31 | 70.08% | $1.13 Billion | $1.61 Billion | +21.07pp |
| 2018-12-31 | 49.01% | $324.33 Million | $661.70 Million | +3.48pp |
| 2017-12-31 | 45.54% | $202.64 Million | $444.98 Million | +39.08pp |
| 2016-12-31 | 6.46% | $7.18 Million | $111.24 Million | -7.10pp |
| 2015-12-31 | 13.56% | $6.81 Million | $50.25 Million | -35.89pp |
| 2014-12-31 | 49.45% | $28.93 Million | $58.51 Million | +47.45pp |
| 2013-12-31 | 2.00% | $690.44K | $34.54 Million | -4.06pp |
| 2012-12-31 | 6.06% | $1.39 Million | $22.93 Million | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more